European Journal of Internal Medicine
Volume 21, Issue 2 , Pages 70-73 , April 2010

Vaccination, squalene and anti-squalene antibodies: Facts or fiction?

  • Giuseppe Lippi

      Affiliations

    • U.O. Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
    • ,
  • Giovanni Targher

      Affiliations

    • Sezione di Endocrinologia, Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Italy
    • ,
  • Massimo Franchini

      Affiliations

    • Servizio di Immunoematologia e Trasfusione, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
    • Corresponding Author InformationCorresponding author. Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.

References 

  1. Bloch KE. Sterol structure and membrane function. CRC Crit Rev Biochem. 1983;14:47–92
  2. Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules. 2009;14:540–554
  3. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin. 2008;4:347–349
  4. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine. 2008;26:3209–3222
  5. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses. 2008;2:243–249
  6. Dormitzer PR, Rappuoli R, Casini F, et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Currents: influenza 2009. Available at http://knol.google.com/k/adjuvant-is-necessary-for-a-robust-immune-response-to-a-single-dose-of-h1n1. Last accessed : 28 November 2009.
  7. Clark TW, Pareek M, Hoschler K, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine — preliminary report. N Engl J Med 2009 Sep 10, Electronic publication.
  8. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563–571
  9. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009 Oct 5 (Electronic publication).
  10. Gronseth GS. Gulf war syndrome: a toxic exposure? A systematic review. Neurol Clin. 2005;23:523–540
  11. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol. 2000;68:55–64
  12. Alving CR, Grabenstein JD. Re: antibodies to squalene in Gulf War Syndrome. Exp Mol Pathol. 2000;68:196–198
  13. Asa PB, Wilson RB, Garry RF. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol. 2002;73:19–27
  14. Matyas GR, Wassef NM, Rao M, Alving CR. Induction and detection of antibodies to squalene. J Immunol Methods. 2000;245:1–14
  15. Matyas GR, Rao M, Alving CR. Induction and detection of antibodies to squalene. II. Optimization of the assay for murine antibodies. J Immunol Methods. 2002;267:119–129
  16. Matyas GR, Rao M, Pittman PR, et al. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J Immunol Methods. 2004;286:47–67
  17. Del Giudice G, Fragapane E, Bugarini R, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol. 2006;13:1010–1013
  18. Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine. 2009;27:3921–3926
  19. In:  Fulco CA,  Liverman CT,  Sox HC editor. Gulf War and Health. Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines. Washington, DC: Institute of Medicine, National Academy Press; 2000;
  20. Everson MP, Shi K, Aldridge P, Bartolucci AA, Blackburn WD. Immunological responses are not abnormal in symptomatic Gulf War veterans. Ann NY Acad Sci. 2002;966:327–342
  21. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother. 2004;58:325–337
  22. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin Pharmacol Ther. 2007;82:740–744
  23. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2003;2:197–203

PII: S0953-6205(09)00244-1

doi: 10.1016/j.ejim.2009.12.001

European Journal of Internal Medicine
Volume 21, Issue 2 , Pages 70-73 , April 2010

Article Tools